PDF(Pubmed)
Abstract：
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the management of type 2 diabetes and obesity. It was the first GLP-1 receptor agonist to be approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of obesity. To date, numerous skin adverse reactions to liraglutide have been reported, but data regarding hypersensitivity reactions are scarce, raising concerns about its safety and clinical management. We present the case of a 56-year-old female patient with class 3 obesity who was started on subcutaneous liraglutide (Saxenda) by her endocrinologist. One month after starting the aforementioned treatment, the patient presented well-defined, round, erythematous pruriginous plaques surrounding the injection site, around 24 hours after the drug administration. A liraglutide-induced, delayed-type hypersensitivity reaction was suspected, which could be subsequently confirmed by allergy testing and histopathological study. This paper explores the clinical use of liraglutide, the occurrence of hypersensitivity reactions, diagnosis, management, and implications for future research. Understanding and managing liraglutide hypersensitivity is crucial to ensuring the safety and efficacy of this medication.
摘要：
利拉鲁肽是一种胰高血糖素样肽-1（GLP-1）受体激动剂，用于治疗2型糖尿病和肥胖症。它是第一个被美国食品和药物管理局和欧洲药品管理局批准用于治疗肥胖的GLP-1受体激动剂。迄今为止,已经报道了许多利拉鲁肽的皮肤不良反应，但是关于超敏反应的数据很少，引起人们对其安全性和临床管理的担忧。我们介绍了一名56岁的3级肥胖女性患者，她的内分泌学家开始皮下利拉鲁肽（Saxenda）。开始上述治疗一个月后，病人表现得很明确，圆形,注射部位周围的红斑瘙痒斑块，给药后24小时左右。利拉鲁肽诱导的，怀疑是迟发型超敏反应,随后可以通过过敏测试和组织病理学研究证实。本文探讨了利拉鲁肽的临床应用，超敏反应的发生，诊断,管理,以及对未来研究的启示。了解和管理利拉鲁肽超敏反应对于确保该药物的安全性和有效性至关重要。
